Acquisition of Chunrui Medical Equity Sansan special materials to make the pharmaceutical industry

Sansan Special Materials, which has been suspended for three months, announced today that the company intends to acquire 88% of Chongqing Chunrui Pharmaceutical and Chemical Co., Ltd. ("Chunrui Medicalization") for 748 million yuan, while raising no more than 748 million yuan in supporting funds.
note that this is the second time this week that the company announced the acquisition of pharmaceutical assets, the company's determination to become a large pharmaceutical industry can be seen.Acquisition of The Remaining Equity in Chunrui Medical
announced that Sansan Special Materials intends to issue 16.4 million shares to 182 natural person shareholders, including Yan Tingyan, at a price of 30.78 yuan, and pay 243 million yuan in cash, for a total price of 748 million yuan, to acquire 88% of its stake in Chunrui Medical. At the same time, the company intends to issue shares at a price of 35.68 yuan to raise no more than 748 million yuan of supporting funds, the net proceeds will be used to pay the cash value of the assets of the transaction, the target company 2000 tons / year acetamine expansion project, to supplement the working capital of listed companies.
Daily Economic News reporter noted that as early as July 30, 2015, Sansan Special Materials announced that the company's wholly-owned subsidiary Sansan Investment and The Company's controlling shareholders Pan Xianwen, director Yang Xingzhi and Yan Tingyan and other 180 natural persons proposed to jointly increase the capital of Chunrui Medical 60 million shares, of which the company will receive 12% of the shares.
And in its announcement on March 21 this year, Sansan Specials also said, "The Company intends to acquire the equity of a pharmaceutical intermediate production enterprise and raise supporting funds by issuing shares and paying cash." "
facts show that the above-mentioned "a pharmaceutical intermediate production enterprises" is exactly Chunrui medicalization. After the completion of this equity acquisition, Sansan Special Materials will directly and indirectly hold a 100% stake in Chunrui Medical.
data show that Chunrui medical main business for chemical and pharmaceutical raw materials research and development, production and sales. The company's main product quality indicators to meet international standards, including hydrochloric acid Prukain won the title of high-tech products in Chongqing. In the past two years, the company achieved net profit of 22.65 million yuan and 53.25 million yuan, respectively, and net profit of 21.07 million yuan from January to March this year.
, according to the plan, the other party promised that Chunrui Medical's net profit for 2016, 2017 and 2018 would not be less than 55 million yuan, 61 million yuan and 68 million yuan, respectively.Has acquired a 100% stake in Baikang Pharmaceutical Co., Ltd.
In fact, on the 18th of this month, Sansan Specials announced that the company and Liaoyuan City Baikang Pharmaceutical Co., Ltd. (hereinafter referred to as "Baikang Pharmaceuticals") major shareholders signed the "On Liaoyuan City Baikang Pharmaceutical Co., Ltd. 100% equity transfer intention agreement", to buy 100% of Baikang Pharmaceutical Co., Ltd. in cash of no more than 260 million yuan.
information shows that Baikang Pharmaceuticals is mainly engaged in chemical synthesis of raw materials and the corresponding tablets, granules, hard capsules production and sales, the main products are GMP certified and obtained the production of batches of chemicals.
in the field of medicine in a row, showing the determination of Sansant specialty to do big pharmaceutical business. Sansan special materials said that through the acquisition of Chunrui Medical and Baikang Pharmaceuticals, the company will be fully involved in the pharmaceutical industry with a greater room for growth, the formation of pharmaceutical intermediates, raw materials, preparations as one of the pharmaceutical industry chain, to lay the foundation for the diversified development of listed companies. At the same time, the company uses the capital market platform to integrate resources and realize diversified development strategy, which helps listed companies to diversify their operating risks, tap new profit growth points, and better safeguard the interests of shareholders of listed companies.
: If we use your picture, please contact this site for a reward. If you do not wish your work to appear on this site, please contact us to request that your work be removed. (China Economic Network)